So, just to close the loop, the problem, if there is one, is that those analyses showing continuing efficacy for 50% of the population at 6 months were not included in the label. Question is whether this prevents Revance from promoting its product based upon the unincluded analyses.
Is there similar data for Botox, i.e., where the measured duration of effect is based on that EITHER the patient’s self-assessment or the investigator’s assessment was none or mild? Or put another way, how large of a duration advantage does Daxxify have using an apples to apples comparison.
Market Data 
Markets 
AI
